Search the Newsreel

Is Crinetics Pharmaceuticals (CRNX) Undervalued After Q2 Earnings Miss? GF Score: 47/100, Revenue at $25.1M

Crinetics (Nasdaq: CRNX) agrees to $85 cash-per-share sale to Vertex

Crinetics Pharmaceuticals announced it has agreed to be acquired by Vertex Pharmaceuticals for $85.00 per share in cash, totaling approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. The acquisition is expected to close in the third quarter of 2026, pending regulatory …

Crispr Therapeut (CRSP) Stock News & Updates

This page provides news and updates for Crispr Therapeutics (CRSP), a company focused on gene-based medicines. Recent updates include a Q2 2026 financial report showing $76 million in CASGEVY revenue and advancements in multiple clinical programs. The company also announced participation in several investor …

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago. These figures are adjusted for non-recurring items. This …

Cricut (CRCT) holder Ashish Arora plans 60,000-share sale after prior large trades

Ashish Arora, a shareholder in Cricut, Inc. (CRCT), has filed a Form 144 indicating his intent to sell 60,000 shares of Class A common stock through Goldman Sachs & Co. LLC on August 3, 2026, valued at $287,400. These shares were initially acquired as …

Crispr Therapeutics earnings beat by $0.26, revenue topped estimates

Crispr Therapeutics reported a second-quarter EPS of $-0.94, surpassing analyst estimates by $0.26, and revenue of $10.18M, which also topped the consensus estimate. Despite the strong earnings beat, the company's stock price has seen declines over the last three and twelve months. InvestingPro assesses …

Crispr Therapeutics AG (CRSP) rebounds 3.1% before Aug. 3 earnings, but trend stays inactive

The gene-editing biotech reports with medium-term performance still under pressure and volume running below its 13-week average.

CRISPR Therapeutics (NASDAQ:CRSP) Announces Quarterly Earnings Results, Beats Estimates By $0.26 EPS

CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings, reporting an adjusted loss of $0.94 per share, significantly beating analyst estimates of a $1.20 loss. The company also surpassed revenue expectations, bringing in $10.18 million against an estimated $7.45 million. Following these results, CRSP shares rose …

Crinetics Pharmaceuticals GAAP EPS of -$1.14 beats by $0.07, revenue of $25.12M beats by $10.25M

* Crinetics Pharmaceuticals press release [https://seekingalpha.com/pr/20604770-crinetics-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-business] (CRNX [https://seekingalpha.com/symbol/CRNX]): Q2 GAAP EPS of -$1.14 beats by $0.07. * Revenue of $25.12M (+2412.0% Y/Y) beats by $10.25M. * Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net …

Earnings Flash (CRSP) CRISPR Therapeutics AG Reports Q2 Revenue $10.2M, vs. FactSet Est of $7.4M

CRISPR Therapeutics AG (CRSP) reported Q2 revenue of $10.2 million, significantly surpassing the FactSet estimate of $7.4 million. This earnings flash highlights the company's financial performance for the second quarter and six months ended June 30, 2026. The article also mentions the company's recent …

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results

ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni, Ph.D., Chairman and …

Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q2 Revenue $25.1M, vs. FactSet Est of $14.8M

Crinetics Pharmaceuticals, Inc. (CRNX) announced its Q2 revenue of $25.1 million, significantly exceeding the FactSet estimate of $14.8 million. The company is a clinical-stage pharmaceutical firm specializing in treatments for rare endocrine diseases and endocrine-related tumors, with lead candidates PALSONIFY and Atumelnant. This strong …

CRISPR Therapeutics reports $91.2 million second quarter net loss

CRISPR Therapeutics (CRSP) reported a net loss of $91.2 million for the second quarter of 2026, a significant improvement from the $208.5 million loss in the same period last year, while total revenue increased to $10.2 million. The company's gene-editing therapy, CASGEVY, generated $76 …

Strata Critical Medical (SRTA) CEO granted 57,172 shares from PSU vesting

Strata Critical Medical, Inc. CEO, Scott M. Wunsch, was granted 57,172 shares of Class A common stock on July 30, 2026, due to the vesting of performance-based restricted stock units (PSUs). A portion of these shares, 13,992, were withheld on July 31, 2026, at …

Strata Critical Medical (SRTA) awards 30,913 RSUs to board director

Strata Critical Medical, Inc. (SRTA) board director Philip Edward M was granted 30,913 Restricted Stock Units (RSUs) on July 30, 2026. These RSUs will vest 100% on the date of the company's 2027 Annual Meeting of Stockholders and will be settled in Class A …

Director RSU award: Strata Critical Medical (SRTA) grants 50,234 units

Strata Critical Medical (SRTA) director Robert S. Wiesenthal was granted 50,234 Restricted Stock Units (RSUs) on July 30, 2026. These RSUs, which have a stated price of $0.0000 per share, will fully vest on the date of the company's 2027 Annual Meeting of Stockholders. …

Strata Critical Medical (SRTA) reports PSU vesting and tax share withholding

Strata Critical Medical (SRTA) CAO gets PSU shares; 34,015 withheld

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Crinetics Pharmaceuticals, Inc. Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- …

Critical Metals (NASDAQ:CRML) Shares Surge 16% as Policy Optimism Clashes with Stock Supply

Critical Metals (NASDAQ:CRML) shares surged 15.6% due to policy optimism regarding U.S. investment in critical minerals and stricter sourcing regulations. This surge increased its implied equity value by approximately $126 million, despite no new company announcement. The company continues to focus on its Tanbreez …

Canaccord raises Neurocrine Bio price target on strong sales beat

Canaccord Genuity increased its price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX) from $200 to $210, maintaining a Buy rating, following the company's strong second-quarter performance. Neurocrine's sales for Ingrezza and Crenessity significantly exceeded analyst estimates, contributing to a 34% revenue growth. The company …

Trading Systems Reacting to (CRNX) Volatility

This article analyzes Crinetics Pharmaceuticals Inc. (CRNX) using AI models to provide trading strategies. It notes a neutral near and mid-term outlook but a positive long-term bias, with no resistance levels above the current price suggesting upside potential. The report details position trading, momentum …

Carter's Q2 Earnings Beat Estimates on Wholesale and Retail Gains

Carter's, Inc. (CRI) reported strong second-quarter 2026 results, surpassing earnings and revenue estimates driven by gains across its U.S. Retail and Wholesale segments. Despite a contraction in adjusted gross margin due to tariff costs, the company saw increased adjusted operating income and maintained a …

Tangible book value per share of Criteo SA – BX:CRTO

This page provides financial data for Criteo SA (BX:CRTO), specifically its tangible book value per share. The content indicates market information, financial overviews, and other trading-related data for the company. The page itself is a snapshot of financial metrics provided by TradingView.

Price to cash flow ratio of Criteo SA – BX:CRTO

This article provides financial information for Criteo SA (BX:CRTO), specifically focusing on its price to cash flow ratio. It details that the market is closed with no trades and gives an overview of available financial data and community features on TradingView for this stock.

Crizac Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss of $0.94 per Share

CRISPR Therapeutics AG (CRSP) reported a Q2 loss of $0.94 per share on revenue of $10.18 million, missing analyst revenue estimates but exceeding them on earnings per share. The company saw significant growth in revenue from its lead drug, CASGEVY, with a 151% year-over-year …

Crimson Tide plc Reports Earnings Results for the Full Year Ended April 30, 2026

Farallon discloses 8.5% Crinetics stake in Schedule 13G/A (CRNX)

Farallon Capital Management, L.L.C. has disclosed an 8.5% beneficial ownership stake in Crinetics Pharmaceuticals, Inc. (CRNX) through a Schedule 13G/A filing. As of June 30, 2026, Farallon holds 8,989,098 shares of Crinetics' common stock across several investment partnerships, with senior members Joshua J. Dapice …

H.C. Wainwright reiterates Neurocrine Bio stock rating on pipeline progress By Investing.com

H.C. Wainwright has reaffirmed its Buy rating and $215.00 price target for Neurocrine Biosciences Inc. (NASDAQ: NBIX), citing the company's strong pipeline progress and financial performance. The company reported significant revenue growth and provided updates on its clinical trials for osavampator and direclidine, which …

Carter's (CRI) Stock Profit Beat Meets Lingering Margin Pressure

Carter's net sales up 5 percent in Q2 2026, exceeds prior outlook

Carter's, a US kidswear company, announced its Q2 2026 financial results, showing a 5.2 percent increase in net sales to $615.50 million and a significant rise in operating income to $139.80 million, exceeding prior expectations. This growth was attributed to a recovery of import …

Scribe Therapeutics Inc. (SCTX) Revenue (TTM)

Crinetics Q2 Revenue Rises to $25.1 Million Ahead of Vertex Deal

Strata Critical Medical (SRTA) co-CEO receives PSU share awards

Crimson Tide plc Reports £0.2m Pre-Tax Profit in FY26 and Secures Record £3.9m Retail Contract